Yael Cohen, MD, on Entering an Era of CAR T-Cell Therapy for Myeloma

Video

Yael Cohen, MD, sat down with CancerNetwork® to discuss how the multiple myeloma space is entering into an era of CAR T-cell therapy.

In an interview with CancerNetwork®, Yael Cohen, MD, a senior physician in the Department of Hematology at Tel-Aviv Sourasky Medical Center, discussed how findings from the phase 2 CARTITUDE-2 trial (NCT04133636), examining ciltacabtagene autoleucel (cilta-cel) in lenalidomide (Revlimid)–refractory multiple myeloma, may be indicative of the space entering an era of CAR T-cell therapies.

Transcript:

We are on the verge of a new era for myeloma because [cilta-cel] is a very potent therapy. Certainly, we will have to learn how to use it and for which patients. There are challenges with CAR T therapy, [logistically and] it's also a very expensive therapy; thought would have to be given to this, as well. Our hope is that treating patients earlier in their disease course, perhaps when their T cells are less exhausted and their disease might be not as anaplastic, that we will [provide] cure for some of the patients. [It's] early in the game, but certainly [with] the very deep responses and [minimal residual disease] negativity, perhaps for some patients, we will get there.

Reference

Cohen YC, Cohen AD, Delforge M, et al. Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: updated results from CARTITUDE-2. Presented at: 2021 ASH Annual Meeting; December 11-13, 2021; Atlanta, GA. Poster 3866.

Recent Videos
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Related Content